JP Morgan Chase’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,000
| Closed | -$377K | – | 7509 |
|
|
2025
Q4 | $377K | Buy |
+15,000
| New | +$352K | ﹤0.01% | 5203 |
|
|
2024
Q1 | – | Sell |
-61,800
| Closed | -$3.7M | – | 7381 |
|
|
2023
Q4 | $3.7M | Sell |
61,800
-494,500
| -89% | -$25.1M | ﹤0.01% | 3349 |
|
|
2023
Q3 | $21.2M | Buy |
556,300
+471,000
| +552% | +$20.7M | ﹤0.01% | 1636 |
|
|
2023
Q2 | $7.77M | Sell |
85,300
-279,400
| -77% | -$24.1M | ﹤0.01% | 2506 |
|
|
2023
Q1 | $24.1M | Buy |
364,700
+360,700
| +9,018% | +$20.8M | ﹤0.01% | 1532 |
|
|
2022
Q4 | $207K | Sell |
4,000
-68,500
| -94% | -$3.63M | ﹤0.01% | 5019 |
|
|
2022
Q3 | $4.95M | Buy |
+72,500
| New | +$4.29M | ﹤0.01% | 2747 |
|
|
2022
Q2 | – | Sell |
-165,500
| Closed | -$8.41M | – | 6437 |
|
|
2022
Q1 | $8.41M | Buy |
+165,500
| New | +$7.31M | ﹤0.01% | 2543 |
|
|
2021
Q4 | – | Sell |
-113,100
| Closed | -$3.73M | – | 6612 |
|
|
2021
Q3 | $3.73M | Buy |
113,100
+83,400
| +281% | +$4.69M | ﹤0.01% | 3292 |
|
|
2021
Q2 | $1.88M | Buy |
29,700
+24,300
| +450% | +$1.25M | ﹤0.01% | 3839 |
|
|
2021
Q1 | $232K | Buy |
+5,400
| New | +$256K | ﹤0.01% | 5085 |
|
|
2020
Q1 | – | Sell |
-206,500
| Closed | -$6.32M | – | 5272 |
|
|
2019
Q4 | $6.32M | Buy |
+206,500
| New | +$5.72M | ﹤0.01% | 2501 |
|
Other funds holding APLS
JP Morgan Chase's APLS Position: Q2 2026 in Review
JP Morgan Chase sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,047,927 shares — an estimated $35M sold.
JP Morgan Chase first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $163M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- JP Morgan Chase reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 2,047,927 Apellis Pharmaceuticals shares in Q2 2026, an estimated $35M.
- JP Morgan Chase first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- JP Morgan Chase's Apellis Pharmaceuticals position peaked at $163M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.